



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,

Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 26th August, 2025

To
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Security Code: 532815

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E), Mumbai
- 400 051.
Symbol: SMSPHARMA

Dear Sir/Madam,

**Sub: Receipt of Establishment Inspection Report (EIR) for Central Laboratory Analytical Services
Gagillapur, Hyderabad**

Ref: Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

We wish to inform you that, the Company has received the Establishment Inspection Report from United States Food and Drug Administration (USFDA) for the inspection conducted during June, 2025 at the Company's Central Laboratory Analytical Services located at Gagillapur Village, Medchal Malkajgiri District, Hyderabad, Telangana.

Please find the enclosed Company statement titled "**Establishment Inspection Report received for Central Laboratory Analytical Services**"

The above information will also be made available on the website of the Company at www.smspharma.com

This is for your information and records.

Thanking you

Yours Faithfully
For SMS Pharmaceuticals Limited

Thirumalesh Tumma
Company Secretary



August 26, 2025

Establishment Inspection Report (EIR) received for Central Laboratory Analytical Services

SMS Pharmaceuticals Limited (SMS Pharma) (NSE: SMSPHARMA; BSE:532815) is pleased to announce the successful closure of the recent inspection by the USFDA at its Central Laboratory Analytical Services, Gagillapur, Hyderabad, with the receipt of the Establishment Inspection Report (EIR).

The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations, as previously intimated to the stock exchanges. The company has received the Establishment Inspection Report (EIR) with "No Action Indicated" (NAI) status, marking the closure of the audit.

Commenting on this achievement, Mr. P. Vamsi Krishna, Executive Director, stated:

"The successful completion of the recent USFDA inspection underscores our unwavering commitment to the highest standards of quality, regulatory compliance, and operational excellence across our manufacturing and analytical facilities. This positive outcome reinforces the confidence of our global partners and stakeholders, while further enabling our strategic growth and sustained presence in key regulated markets."

About SMS Pharmaceuticals Limited

Established in 1990, SMS Pharmaceuticals Limited is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers. The Company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. Supported by strong in-house R&D capabilities, the Company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries.

DISCLAIMER

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. SMS Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and discussions; undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.